Iopamidol
(Synonyms: 碘帕醇; B-15000; SQ-13396) 目录号 : GC36324
Iopamidol (Iopamiro, Isovue, Iopamiron, Niopam, Solutrast,B-15000,SQ-13396) is a non-ionic, water-soluble radiographic contrast agent.
Cas No.:60166-93-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Iopamidol (Iopamiro, Isovue, Iopamiron, Niopam, Solutrast,B-15000,SQ-13396) is a non-ionic, water-soluble radiographic contrast agent.
Iopamidol significantly decreases the rate of atrial contraction to a greater extent than either formulation of iodixanol. Iopamidol decreases papillary muscle force development more than the sodium formulation of iodixanol[3].
Iopamidol increases systolic blood pressure (SBP), mean arterial pressure (MAP), and peak left ventricular pressure (LVP). Iopamidol increases LVP and LV end diastolic pressure to a greater extent than the cationic formulation of iodixanol. Thus iopamidol affects cardiovascular parameters more than iodixanol[3].
[1] Longo DL, et al. Magn Reson Med. 2011, 65(1):202-11. [2] Doan R, et al. 55th Annual Meeting of the Orthopaedic Research Society. Poster No.2166 [3] Dundore RL, et al. Invest Radiol. 1991, 26(8):715-21.
| Cas No. | 60166-93-0 | SDF | |
| 别名 | 碘帕醇; B-15000; SQ-13396 | ||
| Canonical SMILES | O=C(C1=C(I)C(NC([C@@H](O)C)=O)=C(I)C(C(NC(CO)CO)=O)=C1I)NC(CO)CO | ||
| 分子式 | C17H22I3N3O8 | 分子量 | 777.09 |
| 溶解度 | Water: ≥ 8.2 mg/mL (10.55 mM) | 储存条件 | Store at -20°C,protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2869 mL | 6.4343 mL | 12.8685 mL |
| 5 mM | 0.2574 mL | 1.2869 mL | 2.5737 mL |
| 10 mM | 0.1287 mL | 0.6434 mL | 1.2869 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
INTRAVENOUS Iopamidol PHARMACOKINETICS IN COMMON CARP ( CYPRINUS CARPIO)
J Zoo Wildl Med 2021 Jan;51(4):889-895.PMID:33480569DOI:10.1638/2020-0085.
Koi carp (Cyprinus carpio), a variety of common carp, has gained popularity as an ornamental fish worldwide. Their high monetary and sentimental value has necessitated the development of antemortem diagnostic options. Contrast-enhanced computed tomography (CT) scanning with intravenous Iopamidol has been shown to be safe and diagnostically effective at a minimum dose of 480 mg iodine (I)/kg in koi. The purpose of this study was to evaluate the pharmacokinetic parameters of this dose of Iopamidol, as well as excretory mechanisms specific to fish, using common carp as a model. Blood, posterior kidney, gill, and bile were collected, necessitating sacrificial sampling. Thirty-five adult fish were randomly divided into six sampling groups. Five sampling groups (n = 6/group) received 480 mg I/kg; the control group (n = 5) received an equivalent volume of saline. The Iopamidol groups were sampled at the following time points postinjection: 5 min, 1 hr, 6 hr, 24 hr, and 48 hr. The control group was sampled at 48 hr. Concentrations of Iopamidol were determined using liquid chromatography tandem mass spectrometry; noncompartmental analysis was used to calculate pharmacokinetic parameters. Total clearance (3.04 ml/hr per kilogram) was slower, the volume of distribution smaller (79.92 ml/ kg), and the elimination half-life (20.39 hr) prolonged compared to similar studies in mammals. The time-concentration profiles of kidney and gill were similar; these organs appear to be responsible for the majority of Iopamidol excretion. However, that of bile was much different, showing slower, low-level accumulation with time, suggesting that in fish, multiple organ systems play a role in elimination beyond just the kidney. In particular, they may rely more heavily upon biliary excretion, which thus far has been noted only in mammals with renal impairment. Further research is warranted to investigate if the slower elimination allows diagnostic CT images to be acquired at different time points postinjection.
Transformation of Iopamidol during chlorination
Environ Sci Technol 2014 Nov 4;48(21):12689-97.PMID:25325766DOI:10.1021/es503609s.
The transformation of the iodinated X-ray contrast media (ICM) Iopamidol, iopromide, iohexol, iomeprol, and diatrizoate was examined in purified water over the pH range from 6.5 to 8.5 in the presence of sodium hypochlorite, monochloramine, and chlorine dioxide. In the presence of aqueous chlorine, only Iopamidol was transformed. All other ICM did not show significant reactivity, regardless of the oxidant used. Chlorination of Iopamidol followed a second order reaction, with an observed rate constant of up to 0.87 M(-1) s(-1) (±0.021 M(-1) s(-1)) at pH 8.5. The hypochlorite anion was identified to be the reactive chlorine species. Iodine was released during the transformation of Iopamidol, and was mainly oxidized to iodate. Only a small percentage (less than 2% after 24 h) was transformed to known organic iodinated disinfection byproducts (DBPs) of low molecular weight. Some of the iodine was still present in high-molecular weight DBPs. The chemical structures of these DBPs were elucidated via MSn fragmentation and NMR. Side chain cleavage was observed as well as the exchange of iodine by chlorine. An overall transformation pathway was proposed for the degradation of Iopamidol. CHO cell chronic cytotoxicity tests indicate that chlorination of Iopamidol generates a toxic mixture of high molecular weight DBPs (LC50 332 ng/μL).
Chlor(am)ination of Iopamidol: Kinetics, pathways and disinfection by-products formation
Chemosphere 2017 Oct;184:489-497.PMID:28618281DOI:10.1016/j.chemosphere.2017.06.012.
The degradation kinetics, pathways and disinfection by-products (DBPs) formation of Iopamidol by chlorine and chloramines were investigated in this paper. The chlorination kinetics can be well described by a second-order model. The apparent second-order rate constants of Iopamidol chlorination significantly increased with solution pH. The rate constants of Iopamidol with HOCl and OCl- were calculated as (1.66 ± 0.09) × 10-3 M-1 s-1 and (0.45± 0.02) M-1 s-1, respectively. However, the chloramination of Iopamidol fitted well with third-order kinetics and the maximum of the apparent rate constant occurred at pH 7. It was inferred that the free chlorine (i.e., HOCl and OCl-) can react with Iopamidol while the combined chlorine species (i.e., NH2Cl and NHCl2) were not reactive with Iopamidol. The main intermediates during chlorination or chloramination of Iopamidol were identified using ultra performance liquid chromatography - electrospray ionization-mass spectrometry (UPLC-ESI-MS), and the destruction pathways including stepwise deiodination, hydroxylation as well as chlorination were then proposed. The regular and iodinated DBPs formed during chlorination and chloramination of Iopamidol were measured. It was found that iodine conversion from Iopamidol to toxic iodinated DBPs distinctly increased during chloramination. The results also indicated that although chloramines were much less reactive than chlorine toward Iopamidol, they led to the formation of much more toxic iodinated DBPs, especially CHI3.
Efficient degradation and deiodination of Iopamidol by UV/sulfite process: Assessment of typical process parameters and transformation paths
Environ Int 2022 Sep;167:107383.PMID:35952467DOI:10.1016/j.envint.2022.107383.
Iopamidol (IPM) is widely used in medical clinical examination and treatment and has immeasurable harm to the ecological environment. The combination of UV and sulfite (UV/sulfite) process was developed to degrade IPM in this study. In contrast to that almost no removal of IPM was observed under sulfite reduction alone, the UV/sulfite process could efficiently reductively degrade IPM with the observed rate constant (kobs) of 2.08 min-1, which was nearly 4 times that of UV irradiation alone. The major active species in the UV/sulfite process were identified as hydrated electrons (eaq-) by employing active species scavengers. The influence of the initial pH, sulfite dosage, IPM concentration, UV intensity and common water matrix were evaluated. The degradation of IPM reached nearly 100% within only 2.5 min at pH 9, and kobs increased at higher initial sulfite dosages and greater UV intensities. HCO3- had a limited effect on the degradation of IPM, while humic acid (HA) was found to be a strong inhibitor in the UV/sulfite process. With the synergistic action of UV/sulfite, most of the iodine in IPM was found to release in the form of iodide ions (up to approximately 98%), and a few formed iodide-containing organic compounds, reducing significantly the toxicity of degradation products. Under direct UV irradiation and free radical reduction (mainly eaq-), 15 transformation intermediates of IPM were produced by amide hydrolysis, deiodination, hydroxyl radical addition and hydrogen abstraction reactions, in which free radical attack accounted for the main part. Consequently, the UV/sulfite process has a strong potential for IPM degradation in aquatic environments.
[Separation and purification of Iopamidol using preparative high-performance liquid chromatography]
Se Pu 2018 Oct 8;36(10):1061-1066.PMID:30378367DOI:10.3724/SP.J.1123.2018.06001.
The development and optimization of separation and purification methods for high-purity Iopamidol were performed based on preparative high-performance liquid chromatography (prep-HPLC). In this study, a reversed-phase separation method for the analysis of Iopamidol was developed first. The effects of chromatographic parameters, including two kinds of stationary phase with different bonded amounts, column temperature, and sample loading capacity, on the retention, resolution, and peak shape of Iopamidol were investigated. The results showed that good retention and resolution of Iopamidol were realized on a C18-1 column (250 mm×4.6 mm, 10 μm) of which the bonded amount was 13.7%. Retention of Iopamidol was weakened with increasing column temperature, resulting in a low resolution between Iopamidol and impurities. Thus, the column temperature was adjusted to 20-30℃. Meanwhile, the increasing of loading capacities was also detrimental to retention of Iopamidol or removal of impurities. Prep-HPLC was performed on the C18-1 column (270 mm×50 mm, 10 μm) with the mobile phase of water-methanol at a column temperature of 20℃. After preparation, the chromatographic purity of the Iopamidol sample was 98.97% with recovery of 93.44%, and its related substances all met limited requirements. This method can reduce the impurity level effectively with a high recovery rate, which is helpful for the development of separation and purification of iopamide.